Alembic Pharmaceuticals saw its share surge today after getting approval from the US Food & Drug Administration (USFDA) for its Albendazole Tablets USP, 200 mg. As of 1:40 PM, the company’s shares were trading at ₹1,155.40 on the National Stock Exchange (NSE), up 3.51% from the previous close.
Alembic Pharmaceuticals Ltd has received final approval from the US Food and Drug Administration (USFDA) for its Albendazole Tablets USP, 200 mg.
Albendazole tablets are used to treat neurocysticercosis created by the pork tapeworm and cystic hydatid disease of the liver, lung and peritoneum caused by the dog tapeworm. Alembic now holds 214 ANDA approvals from the USFDA, including 186 final approvals and 28 tentative approvals.